Modifiable risk factors like maternal education, home stability, and early CF therapy significantly improve lung health outcomes in CF, while non-modifiable factors like CFTR genotype and meconium ileus predict poorer outcomes (Table 2). This evidence concerns the gene CFTR and cystic fibrosis.